CARVYKTIHCP.COM: Keyword Density Checker

Total words: 1478 | 2-word phrases: 379 | 3-word phrases: 419 | 4-word phrases: 438

PAGE INFO

Title	Try to keep the title under 60 characters (52 characters) HCP Website \| CARVYKTI® (ciltacabtagene autoleucel)
Description	Try to keep the meta description between 50 - 160 characters (167 characters) View the official healthcare professional (HCP) website for CARVYKTI® (ciltacabtagene autoleucel). See Safety & Prescribing information, including Boxed Warning.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (34 characters) POWERFUL RESULTS AS EARLY AS 2L1

#	Keyword	Frequency	Density
1	immunomodulatory agent a	3	0.72%
2	carvykti® prescribing information	3	0.72%
3	get in touch	3	0.72%
4	adult patients with	3	0.72%
5	and an immunomodulatory	3	0.72%
6	an immunomodulatory agent	3	0.72%
7	intenttotreat analysis set	2	0.48%
8	line of therapy	2	0.48%
9	proteasome inhibitor and	2	0.48%
10	inhibitor and an	2	0.48%
11	janssen biotech inc	2	0.48%
12	study design learn	2	0.48%
13	learn more about	2	0.48%
14	immunomodulatory agent and	2	0.48%
15	go to patient	2	0.48%
16	agent and are	2	0.48%
17	1 prior line	2	0.48%
18	have received a	2	0.48%
19	who have received	2	0.48%
20	in touch carvykti®	2	0.48%
21	to patient website	2	0.48%
22	prior line of	2	0.48%
23	patients with relapsed	2	0.48%
24	least 1 prior	2	0.48%
25	of response duration	2	0.48%
26	at least 1	2	0.48%
27	2024 all rights	2	0.48%
28	depth of response	2	0.48%
29	for the treatment	2	0.48%
30	received at least	2	0.48%

#	Keyword	Frequency	Density
1	an immunomodulatory agent a	3	0.68%
2	and an immunomodulatory agent	3	0.68%
3	received at least 1	2	0.46%
4	who have received a	2	0.46%
5	an immunomodulatory agent and	2	0.46%
6	immunomodulatory agent and are	2	0.46%
7	proteasome inhibitor and an	2	0.46%
8	inhibitor and an immunomodulatory	2	0.46%
9	go to patient website	2	0.46%
10	depth of response duration	2	0.46%
11	of response duration of	2	0.46%
12	get in touch carvykti®	2	0.46%
13	adult patients with relapsed	2	0.46%
14	prior line of therapy	2	0.46%
15	1 prior line of	2	0.46%
16	least 1 prior line	2	0.46%
17	at least 1 prior	2	0.46%
18	design learn about resources	1	0.23%
19	learn about resources for	1	0.23%
20	carvykti® ciltacabtagene autoleucel logo	1	0.23%
21	study design learn about	1	0.23%
22	access and reimbursement get	1	0.23%
23	safety profile study design	1	0.23%
24	the safety profile study	1	0.23%
25	see the safety profile	1	0.23%
26	profile see the safety	1	0.23%
27	review the carvykti® safety	1	0.23%
28	design review the carvykti®	1	0.23%
29	profile study design learn	1	0.23%
30	get access resources resources	1	0.23%
31	and reimbursement get access	1	0.23%
32	a randomized open label	1	0.23%
33	of carvykti® for the	1	0.23%
34	safety of carvykti® for	1	0.23%
35	and safety of carvykti®	1	0.23%
36	efficacy and safety of	1	0.23%
37	the efficacy and safety	1	0.23%
38	evaluating the efficacy and	1	0.23%
39	label multicenter controlled study	1	0.23%
40	open label multicenter controlled	1	0.23%

#	URL	Whois	Check
1	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf	Whois	janssenlabels.com
2	https://www.carvyktiREMS.com	Whois	carvyktiREMS.com
3	https://www.carvykti.com	Whois	carvykti.com
4	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf	Whois	janssenlabels.com
5	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi-es.pdf	Whois	janssenlabels.com
6	https://www.carvyktiREMS.com	Whois	carvyktiREMS.com
7	https://www.carvykti.com	Whois	carvykti.com
8	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf	Whois	janssenlabels.com
9	https://www.janssen.com/oncology	Whois	janssen.com
10	https://legendbiotech.com/	Whois	legendbiotech.com